Skip to main content
CHEMCLIN DIAGNOSTICS CO., LTD. logo

CHEMCLIN DIAGNOSTICS CO., LTD. — Investor Relations & Filings

Ticker · 688468 ISIN · CNE100005311 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2024-05-05 Transaction in Own Shar…
Country CN China
Listing Shanghai Stock Exchange 688468

About CHEMCLIN DIAGNOSTICS CO., LTD.

https://www.chemclin.com/

CHEMCLIN DIAGNOSTICS CO., LTD. specializes in the research, development, and manufacturing of in vitro diagnostic systems and reagents. The company is primarily recognized for its proprietary Light-initiated Chemiluminescent Assay (LiCA) technology, a homogeneous chemiluminescence platform that eliminates the need for washing steps, thereby enhancing testing efficiency and precision. Its product portfolio includes fully automated immunoassay analyzers and a comprehensive range of diagnostic kits covering infectious diseases, cardiac markers, thyroid function, tumor markers, and reproductive health. By integrating advanced biotechnology with automated instrumentation, the company provides clinical laboratories and medical institutions with high-sensitivity diagnostic solutions designed to improve patient care and laboratory workflow.

Recent filings

Filing Released Lang Actions
科美诊断技术股份有限公司关于以集中竞价交易方式回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from the company about its share repurchase (buyback) plan and progress. It details the amount of shares repurchased, the price range, the purpose of the repurchase (employee stock ownership plan or equity incentives), and compliance with relevant regulations. It does not contain financial statements or earnings data, nor is it a report or presentation. It is a formal disclosure of a transaction in the company's own shares. Therefore, the document fits the category of 'Transaction in Own Shares' (POS). The document length is short and focused solely on the buyback update, confirming it is not a full financial report or other type of filing.
2024-05-05 Chinese
中信证券股份有限公司关于科美诊断技术股份有限公司2023年度募集资金存放与使用情况的专项核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from CITIC Securities Co., Ltd. regarding the special verification opinion on the deposit and use of raised funds by Kemei Diagnostic Technology Co., Ltd. for the year 2023. It includes specific financial figures about the amount raised, usage, balance, management systems, agreements, and cash management of the raised funds. It also contains an accountant's verification report conclusion and the sponsor's special verification report conclusion. The document is lengthy (6573 characters) and contains substantive financial data and analysis related to the use of raised funds for the fiscal year 2023. This matches the characteristics of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles related to specific financial matters, here focusing on the raised funds usage and compliance. It is not a full Annual Report (10-K) or Interim Report (IR) as it focuses specifically on the raised funds usage and verification. It is not a simple announcement or certification, so it is not RPA or RNS. Therefore, the best classification is AR with high confidence. FY 2023
2024-04-29 Chinese
科美诊断技术股份有限公司非经营性资金占用及其他关联资金往来情况汇总表的专项审计报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项审计报告" which translates to a "special audit report" regarding non-operating fund occupation and other related party fund transactions for the year 2023. It is prepared by an audit firm (信永中和会计师事务所) and includes detailed tables of fund usage and related party transactions. The content is focused on audit findings and financial data related to specific fund usage rather than a full annual report or interim report. It is not a general annual report (10-K), nor a management report or earnings release. It is a standalone audit report on a specific issue, fitting the definition of Audit Report / Information (AR). The document length is 1738 characters, which is short but contains substantive audit content, not just an announcement or certification. Therefore, the best classification is AR with high confidence. FY 2023
2024-04-29 Chinese
科美诊断技术股份有限公司2023年度内部控制审计报告
Regulatory Filings
2024-04-29 Chinese
科美诊断技术股份有限公司2023年度募集资金存放与使用情况鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2023年度募集资金存放与使用情况鉴证报告" which translates to "2023 Annual Verification Report on the Storage and Use of Raised Funds." It is issued by a certified public accounting firm (ShineWing) and includes detailed financial data about the company's raised funds, their storage, usage, and management for the year 2023. The document contains specific financial figures, tables, and explanations about the use of funds raised from the company's initial public offering. It is a specialized report focusing on the verification of the use and storage of raised capital, which is distinct from a full annual report or earnings release. This type of report aligns with the category of Audit Report / Information (AR), as it is a standalone audit/verification report related to a specific financial aspect (raised funds) and not a full annual report or other category. The document length (over 14,000 characters) and detailed financial content confirm it is the report itself, not just an announcement or certification letter. Therefore, the appropriate classification is AR with high confidence. FY 2023
2024-04-29 Chinese
科美诊断技术股份有限公司独立董事2023年度述职报告（仲人前）
Regulatory Filings
2024-04-29 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.